Takenaka Shigeyuki, Todaka Takashi, Nakamura Matayoshi, Hori Tsuguhide, Iida Takao, Yamada Taketo, Hata Jun-ichi
Department of Public Hygiene, Fukuoka Institute of Health and Environmental Sciences, Dazaifu, Japan.
Chemosphere. 2002 Oct;49(2):161-72. doi: 10.1016/s0045-6535(02)00288-6.
We measured PCDDs/DFs levels in Japanese human livers and adipose tissues in 1999, and TEQ were calculated with WHO TEF. The mean total levels of PCDDs/DFs in livers and adipose tissues were 57 pg TEQ/g on a lipid basis and 49 pg TEQ/g on a lipid basis, respectively. 1,2,3,6,7,8-HxCDD, 1,2,3,4,6,7,8-HpCDD, OCDD, 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 2,3,4,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF and 1,2,3,4,6,7,8-HpCDF concentrations in livers considerably differed from those in 1989 (p < 0.05). The mean non-ortho-chlorine substituted biphenyls levels showed 20 pg TEQ/g on a lipid basis and 17 pg TEQ/g on a lipid basis in livers and adipose tissues, respectively. In livers, the mean of 3,3',4,4'-TCB concentrations was 131 pg/g on a lipid basis, and 7.7-fold higher than that in 1989. The mean total mono-ortho-chlorine substituted biphenyls level was 13.0 pg TEQ/g on a lipid basis in livers and 21.6 pg TEQ/g on a lipid basis in adipose tissues. 3,3',4,4',5-PeCB and 3,3',4,4',5,5'-HxCB levels decreased in adipose tissues, and 3,3',4,4',5-PeCB level only decreased in livers. PCDDs, PCDFs, and mono- and non-ortho-chlorine substituted biphenyls levels may have decreased in livers and adipose tissues because of a governmental policy on dioxins discharge for the decade. Then, we estimated the correlations of PCDDs, PCDFs and the related compound levels between livers and adipose tissues. The correlative PCDDs congeners may have had a similar behavior to that between liver and adipose tissue. On the contrary, most PCDFs isomers may have different behavior between liver and adipose tissue, while 2',3,4,4',5-PeCB (IUPAC No. 123) may also have a different behavior between liver and adipose tissue.
1999年,我们测量了日本人肝脏和脂肪组织中多氯二苯并二噁英/多氯二苯并呋喃(PCDDs/DFs)的含量,并根据世界卫生组织毒性当量因子(WHO TEF)计算了毒性当量(TEQ)。肝脏和脂肪组织中PCDDs/DFs的总平均含量分别为基于脂质的57 pg TEQ/g和49 pg TEQ/g。肝脏中1,2,3,6,7,8-六氯二苯并二噁英、1,2,3,4,6,7,8-七氯二苯并二噁英、八氯二苯并二噁英、2,3,4,7,8-五氯二苯并呋喃、1,2,3,4,7,8-六氯二苯并呋喃、1,2,3,6,7,8-六氯二苯并呋喃、2,3,4,6,7,8-六氯二苯并呋喃、1,2,3,7,8,9-六氯二苯并呋喃和1,2,3,4,6,7,8-七氯二苯并呋喃的浓度与1989年相比有显著差异(p < 0.05)。肝脏和脂肪组织中平均非邻位氯取代联苯的含量分别为基于脂质的20 pg TEQ/g和17 pg TEQ/g。在肝脏中,3,3',4,4'-四氯联苯的平均浓度为基于脂质的131 pg/g,比1989年高7.7倍。肝脏中平均总单邻位氯取代联苯的含量为基于脂质的13.0 pg TEQ/g,脂肪组织中为基于脂质的21.6 pg TEQ/g。脂肪组织中3,3',4,4',5-五氯联苯和3,3',4,4',5,5'-六氯联苯的含量下降,肝脏中仅3,3',4,4',5-五氯联苯的含量下降。由于政府在十年间对二噁英排放的政策,肝脏和脂肪组织中PCDDs、PCDFs以及单邻位和非邻位氯取代联苯的含量可能有所下降。然后,我们估计了肝脏和脂肪组织中PCDDs、PCDFs及相关化合物含量之间的相关性。相关的PCDDs同系物在肝脏和脂肪组织之间的行为可能相似。相反,大多数PCDFs异构体在肝脏和脂肪组织之间的行为可能不同,而2',3,4,4',5-五氯联苯(IUPAC编号123)在肝脏和脂肪组织之间的行为也可能不同。